Identification and selective inhibition of patient-specific pathobionts in inflammatory bowel disease

Background The microbiome has been linked to various chronic diseases. However, the congruency of proposed bacterial taxa between studies is low and identifying inflammation-driving pathobionts for personalised therapy is hampered by a complex microbiota, heterogeneous patient risk factors and technical challenges to sort and maintain viable bacteria. Objective Development of an approach that enables patient-specific identification of bacterial triggers of inflammation and their selective elimination. Design Faecal samples were collected from individual inflammatory bowel disease (IBD) patients during inflammation and remission and transferred into germ-free (GF) mice. Comparing microbiomes collected at different times from the same individual uncoupled the inflammatory capacity of the microbiome from other factors, such as genetic or environmental risk factors. Results We show that inflammatory states of patients with IBD were recapitulated on faecal microbiota transplantation and identified putative disease-driving bacterial taxa by sorting and culture of immunoglobulin-coated intestinal bacteria. Colonisation of GF mice identified Sarcina perfringens and Hathewaya massiliensis as pathobionts promoting inflammation. Mechanistically, innate immune cells required TLR1/2-MyD88 signalling to sense both pathobionts. Compared with healthy individuals, S. perfringens and H. massiliensis were enriched in ~25%–30% and ~5% of patients with IBD, respectively, across diverse populations. S. perfringens abundance was also correlated with mucosal inflammatory transcripts. Both pathobionts increased IL-8 production or reduced ZO-1 expression in IBD patient-derived organoids. Screening >1500-approved compounds revealed five molecules, including oxolinic acid, that selectively inhibited pathobiont growth and protected from intestinal inflammation. Conclusions Collectively, we developed an approach for identifying disease-driving pathobionts and selecting compounds for targeted therapy.

Authors

Institutions

Publication Details

Journal
Gut
Published
2026-11-12
DOI
https://doi.org/10.1136/gutjnl-2026-339262
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Identification and selective inhibition of patient-specific pathobionts in inflammatory bowel disease

Karsten Büringer, Humberto B. Jijon, Marco Tricomi, Cordula Gekeler et al.
Gut
Gut microbiota and health
article

Identification and selective inhibition of patient-specific pathobionts in inflammatory bowel disease

Karsten Büringer, Humberto B. Jijon, Marco Tricomi, Cordula Gekeler, Christian M. Schürch, Mathias F Heikenwälder, Marija Drikic, Kathy D. McCoy, Marcela Davoli Ferreira, Nisar P. Malek, Mehmet Direnç Mungan, Lukas Franz Mager, Christina Ohland, Lisa Maier, Ian A. Lewis, Joachim Fritscher, Patrick Müller, Spencer Abbott, Muhammed Dervis Arslan, Mahana Sabachvili, CAROLYN THOMSON, Hena Ramey
article en

Abstract

Background The microbiome has been linked to various chronic diseases. However, the congruency of proposed bacterial taxa between studies is low and identifying inflammation-driving pathobionts for personalised therapy is hampered by a complex microbiota, heterogeneous patient risk factors and technical challenges to sort and maintain viable bacteria. Objective Development of an approach that enables patient-specific identification of bacterial triggers of inflammation and their selective elimination. Design Faecal samples were collected from individual inflammatory bowel disease (IBD) patients during inflammation and remission and transferred into germ-free (GF) mice. Comparing microbiomes collected at different times from the same individual uncoupled the inflammatory capacity of the microbiome from other factors, such as genetic or environmental risk factors. Results We show that inflammatory states of patients with IBD were recapitulated on faecal microbiota transplantation and identified putative disease-driving bacterial taxa by sorting and culture of immunoglobulin-coated intestinal bacteria. Colonisation of GF mice identified Sarcina perfringens and Hathewaya massiliensis as pathobionts promoting inflammation. Mechanistically, innate immune cells required TLR1/2-MyD88 signalling to sense both pathobionts. Compared with healthy individuals, S. perfringens and H. massiliensis were enriched in ~25%–30% and ~5% of patients with IBD, respectively, across diverse populations. S. perfringens abundance was also correlated with mucosal inflammatory transcripts. Both pathobionts increased IL-8 production or reduced ZO-1 expression in IBD patient-derived organoids. Screening >1500-approved compounds revealed five molecules, including oxolinic acid, that selectively inhibited pathobiont growth and protected from intestinal inflammation. Conclusions Collectively, we developed an approach for identifying disease-driving pathobionts and selecting compounds for targeted therapy.

Gut
University of Calgary (CA), Universitätsklinikum Tübingen (DE), University of Tübingen (DE)
Crohn's and Colitis Foundation of Canada, Canada Foundation for Innovation, Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, International Microbiome Centre, University of Calgary, European Research Council
Good health and well-being
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon